文献速递血栓与止血

抑制剂检测至免疫耐受诱导开始的时间间隔与BrazIT研究中结局的关联

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.
PubMed 文献 · J Thromb Haemost · 2022-09-26

BrazIT研究纳入15家血友病治疗中心的142例重型(FVIII活性<1%)伴高反应性抑制物的遗传性血友病A患者,按抑制剂检测至免疫耐受诱导(ITI)开始的时间间隔(∆tinhi-ITI)四分位分组,评估该间隔与ITI结局的关联;总体成功率为65.5%(93/142),各四分位组间无差异,调整潜在混杂因素后仍无差异。

要点

  • 重型伴高反应性抑制物血友病A患者ITI总体成功率为65.5%(93/142)。
  • ∆tinhi-ITI四分位组间ITI成功率无差异(62.9%、69.4%、58.3%、71.4%)。
  • 延迟开始ITI与ITI失败无关,无论抑制剂检测至ITI开始间隔多久均应提供ITI。

核心结论

  • 延迟开始ITI与重型伴高反应性抑制物血友病A患者的ITI失败无关。
  • 作者认为无论抑制剂检测至ITI开始的间隔多久,均应为此类患者提供ITI。

研究设计与样本

  • BrazIT研究纳入15家血友病治疗中心的142例重型(FVIII活性<1%)伴高反应性抑制物的遗传性血友病A患者,按巴西ITI方案治疗。
  • 按∆tinhi-ITI四分位分层:第一分位0.0-0.6年、第二分位>0.6-1.7年、第三分位>1.7-9.2年、第四分位>9.2-24.5年。
  • ITI结局定义为成功(对外源性FVIII恢复反应性)和失败(对外源性FVIII无反应性且需旁路制剂控制出血)。

主要发现

  • 抑制剂检测时中位年龄3.2岁(四分位距1.6-8.1),ITI开始时中位年龄6.9岁(四分位距2.6-20.1)。
  • 总体ITI成功率为65.5%(93/142)。
  • 第一、第二、第三、第四四分位组ITI成功率分别为62.9%、69.4%、58.3%、71.4%,组间无差异,调整潜在混杂因素后仍无差异。

临床怎么用

  • 作者认为无论抑制剂检测至ITI开始的间隔多久,均应为此类患者提供ITI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune tolerance induction (ITI) is the treatment of choice for eradication of anti-factor VIII (FVIII) neutralizing alloantibodies (inhibitors) in people with inherited hemophilia A and high-responding inhibitor (PwHA-HRi). The association between ITI outcome and time elapsed between inhibitor detection and start of ITI (∆tinhi-ITI ) is debatable. OBJECTIVE: The aim of this study was to evaluate this association among a large cohort of severe PwHA-HRi. METHODS: Severe (factor VIII activity level <1%) PwHA-HRi on ITI (n = 142) were enrolled in 15 hemophilia treatment centers. PwHA-HRi were treated according to the Brazilian ITI Protocol. ITI outcomes were defined as success (i.e., recovered responsiveness to exogenous FVIII) and failure (i.e., no responsiveness to exogenous FVIII and requirement of bypassing agents to control bleeding). RESULTS: Median ages at inhibitor detection and at ITI start were 3.2 years (interquartile range [IQR], 1.6-8.1) and 6.9 years [IQR, 2.6-20.1), respectively. PwHA-HRi were stratified according to ∆tinhi-ITI quartiles: first (0.0-0.6 year), second (>0.6-1.7 year), third (>1.7-9.2 years), and fourth quartile (>9.2-24.5 years). The overall success rate was 65.5% (93/142), with no difference among first, second, third, and fourth quartiles (62.9%, 69.4%, 58.3%, and 71.4%, respectively) even after adjusting the analyses for potential confounders. CONCLUSION: In conclusion, delayed ITI start is not associated with failure of ITI in PwHA-HRi. Therefore, ITI should be offered for these patients, regardless of the time elapsed between the detection of inhibitor and the ITI start.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Camelo RM, Dias MM, Caram-Deelder C, et al. Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study. J Thromb Haemost. 2022. PMID: 36102352. doi:10.1111/jth.15878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。